Associate Professor of Oncology, Associate Professor of Dermatology, Johns Hopkins University School of Medicine
Oncology
Dr. William H. Sharfman, MD
|
|
Give Review
William Sharfman is an expert in the field of Oncology. He studied medicine at University of Toledo College of Medicine. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Dr. William H. Sharfman is a published doctor as well. He has 30 publications published. The latest was: A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma. Dr. William H. Sharfman accepts all Medicare patients.
Publications
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody.
- Phase i/ii trial of 5-Fluorouracil, leucovorin, Zidovudine and dipyridamole for patients with metastatic coloRectal-cancer, renal-cell carcinoma and malignant-melanoma.
- Intensive chemoradiation followed by esophagectomy for squamous Cell and adenocarcinoma of the esophagus.
- Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal Cell carcinoma.
- A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal Cell...
- Anti-CD3 monoclonal antibody treatment of patients with CD3-negative Tumors: a phase IA/B study.
- Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced Cancer.
- Improvements in the staging of cutaneous squamous-cell carcinoma in the 7th edition of the AJCC Cancer Staging Manual.
- A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic Melanoma.
- A phase II study of bortezomib in the treatment of metastatic Malignant melanoma.
- Pediatric Melanoma.
- A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics.
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid Tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
- Conditioned immune response to interferon-gamma in humans.
- A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic Melanoma.
- Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic Melanoma. A phase II Study.
- A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal Cell carcinoma.
- Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T Cells: results from a phase I trial in c...
- Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic Melanoma.
- Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced Cancer.
- The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
- Dose-related immunologic effects of levamisole in patients with Cancer.
- Erythropoietin proDuction. A potential marker for interleukin-2/interferon-responsive tumors.
- Has the Analgesic efficacy of neurolytic celiac plexus block been demonstrated in pancreatic cancer pain?
- Mental neuropathy (numb chin syndrome). A harbinger of tumor progression or relapse.
- Pilot study of interleukin-2 and lymphokine-activated killer Cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patien...
- The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.
Schools
University Of Toledo
Cleveland Clin Hospital
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- Bile Duct Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Cleveland Clinic Foundation -
University of Toledo College of Medicine
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER | 1760413652 | |
| NPPES Provider LastName | SHARFMAN | |
| NPPES Provider FirstName | WILLIAM | |
| NPPES Provider ZIPCode | 210934515 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 242.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 36.0 | |
| Percent Opioid Claims | 14.88 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1760413652 |
| Last Name Of The Provider | SHARFMAN |
| First Name Of The Provider | WILLIAM |
| View All |
Similar Doctors
|
|
Dr. Sandy D. Kotiah, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric J. Seifter, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ross C. Donehower, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Janet Cooper, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Downs, MD |
|
|
Dr. Antonio C. Wolff, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Richard L. Huslig, MD
This Doctor is OpenDoctor Recommended.
|